NAS
RVMD icon

Nykredit A/S’s Revolution Medicines RVMD Stock Holding History

Nykredit A/S’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.41M Buy
+44,928
New +$6.56M 0.03% 383

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Nykredit A/S's RVMD Position: Q2 2026 in Review

Nykredit A/S opened a new position in Revolution Medicines (RVMD) in Q2 2026: 44,928 shares worth $8.41M. The stake represents 0.03% of the portfolio and ranks #383 among its holdings.

694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Nykredit A/S held 44,928 shares of Revolution Medicines worth $8.41M as of Q2 2026.
  • Revolution Medicines was a new Nykredit A/S position in Q2 2026.
  • Revolution Medicines made up 0.03% of Nykredit A/S's portfolio in Q2 2026, its #383 holding.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.